Abstract: Methods for treating a partial or complete rupture of cranial cruciate ligament (CrCL) damage and for preventing or delaying CrCL damage with or without synovitis in dogs are disclosed. For example, this document provides methods for using stem cells and/or progenitor cells to prevent or reduce the likelihood of CrCL rupture in the contralateral leg of mammals, especially dogs, diagnosed with CrCL rupture, as well as methods for using stem cells and/or progenitor cells to treat, delay or prevent complete CrCL rupture in mammals, especially dogs, diagnosed as having a partial CrCL rupture.

Abstract: Transport of containers for biologic products in secure thermal isolation may be facilitated by a containment apparatus. The containment apparatus may include a first component and a second component. The first component may comprise one or more sidewalls that may form an enclosed volume of the first component. The enclosed volume may be fluidly sealed from an environment surrounding the first component and at least partially filled with cooling media. The first component may comprise one or more recessed wells configured to receive at least part of individual containers. At least part of individual recessed wells may come into contact with cooling media within the enclosed volume to facilitate heat transfer between the cooling media and individual containers disposed in individual recessed wells.

Abstract: Methods for treating a partial or complete rupture of cranial cruciate ligament (CrCL) damage and for preventing or delaying CrCL damage with or without synovitis in dogs are disclosed. For example, this document provides methods for using stem cells and/or progenitor cells to prevent or reduce the likelihood of CrCL rupture in the contralateral leg of mammals, especially dogs, diagnosed with CrCL rupture, as well as methods for using stem cells and/or progenitor cells to treat, delay or prevent complete CrCL rupture in mammals, especially dogs, diagnosed as having a partial CrCL rupture.

Abstract: This disclosure provides solutions, systems, and methods for cell, tissue, and/or organ preservation. Some preservation solutions may include any combination of a balanced salt solution, electrolytes, antibiotic agents, antimycotic agents, protease inhibitors, anti-oxidants, simple sugars, starches impermeant ions, uric acid and/or amino acids. Some preservation solutions may also include hydrolyzed collagen. The preservation solutions including hydrolyzed collagen may be used alone or as part of a kit to preserve cells, tissue, or organs. The solution may also be used in connection with one or more medical procedures, for example organ transplantation.

Abstract: This disclosure is directed to synthetic glycoamine compounds and pharmaceutical compositions containing such compounds. The synthetic glycoamine compounds provided here can affect cell adhesion and induce apoptosis, and are useful in treating metastatic diseases and cancer.